Clinical Trial Update: Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis [Phase 4]

View source ↗

Summary

A Phase 4 trial of an injectable biologic with U0279 for severe plaque-type psoriasis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Injectable Biologic (unnamed)
• U0279 (U0279)

Snippet

Sponsor: Stiefel, a GSK Company | Conditions: Plaque Psoriasis | Phase 4 | Status: WITHDRAWN